%0 Journal Article
%A Ko, Andrew H
%A Kim, Kyu-Pyo
%A Siveke, Jens
%A Lopez, Charles D
%A Lacy, Jill
%A O'Reilly, Eileen M
%A Macarulla, Teresa
%A Manji, Gulam A
%A Lee, Jeeyun
%A Ajani, Jaffer
%A Alsina Maqueda, Maria
%A Rha, Sun-Young
%A Lau, Janet
%A Al-Sakaff, Nedal
%A Allen, Simon
%A Lu, Danny
%A Shemesh, Colby S
%A Gan, Xinxin
%A Cha, Edward
%A Oh, Do-Youn
%T Atezolizumab Plus PEGPH20 Versus Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma and Gastric Cancer: MORPHEUS Phase Ib/II Umbrella Randomized Study Platform.
%J The oncologist
%V 28
%N 6
%@ 1083-7159
%C Oxford
%I Oxford University Press
%M DKFZ-2023-00568
%P 553-e472
%D 2023
%Z 2023 Jun 2;28(6):553-e472
%X The MORPHEUS platform comprises multiple open-label, randomized, phase Ib/II trials designed to identify early efficacy and safety signals of treatment combinations across cancers. Atezolizumab (anti-programmed cell death 1 ligand 1 [PD-L1]) was evaluated in combination with PEGylated recombinant human hyaluronidase (PEGPH20).In 2 randomized MORPHEUS trials, eligible patients with advanced, previously treated pancreatic ductal adenocarcinoma (PDAC) or gastric cancer (GC) received atezolizumab plus PEGPH20, or control treatment (mFOLFOX6 or gemcitabine plus nab-paclitaxel [MORPHEUS-PDAC]; ramucirumab plus paclitaxel [MORPHEUS-GC]). Primary endpoints were objective response rates (ORR) per RECIST 1.1 and safety.In MORPHEUS-PDAC, ORRs with atezolizumab plus PEGPH20 (n = 66) were 6.1
%K PD-L1 (Other)
%K basket study (Other)
%K combination therapy (Other)
%K gastric cancer (Other)
%K hyaluronan (Other)
%K immunotherapy (Other)
%K pancreatic cancer (Other)
%K proof of concept (Other)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:36940261
%R 10.1093/oncolo/oyad022
%U https://inrepo02.dkfz.de/record/274366